Cargando…

Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune‐related adverse effect: A case report

A 61‐year‐old woman with stage IVA lung adenocarcinoma exhibited high PD‐L1 expression. Pembrolizumab was administered as second‐line therapy. She developed destructive thyroiditis and her thyroid function started to decline during the administration of three to five courses. She was subsequently di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edahiro, Ryuya, Ishijima, Mikako, Kurebe, Hiroyuki, Nishida, Kohei, Uenami, Takeshi, Kanazu, Masaki, Akazawa, Yuki, Yano, Yukihiro, Mori, Masahide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2019
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500988/ https://www.ncbi.nlm.nih.gov/pubmed/30964601 http://dx.doi.org/10.1111/1759-7714.13065

Ejemplares similares

Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study
por: Yano, Yukihiro, et al.
Publicado: (2018)

Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series
por: Kanazu, Masaki, et al.
Publicado: (2018)

Safety and effectiveness of pirfenidone combined with carboplatin‐based chemotherapy in patients with idiopathic pulmonary fibrosis and non‐small cell lung cancer: A retrospective cohort study
por: Yamamoto, Yuji, et al.
Publicado: (2020)

Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report
por: Kuge, Tomoki, et al.
Publicado: (2021)

EGFR‐mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib
por: Hara, Reina, et al.
Publicado: (2021)

Case series of pleomorphic carcinomas of the lung treated with nivolumab
por: Kanazu, Masaki, et al.
Publicado: (2017)

Radiation Pneumonitis with Eosinophilic Alveolitis in a Lung Cancer Patient
por: Hosono, Yuki, et al.
Publicado: (2017)

Bronchial ethanol injection therapy for airway obstruction in lung cancer patients
por: Okabe, Fukuko, et al.
Publicado: (2021)

Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan
por: Edahiro, Ryuya, et al.
Publicado: (2019)

Non‐small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune‐related adverse events in first‐line treatments with immune checkpoint inhibitors: A retrospective single‐center study
por: Akazawa, Yuki, et al.
Publicado: (2022)

Febrile neutropenia with bacterial paronychia
por: Hosono, Yuki, et al.
Publicado: (2018)

Three Cases of Idiopathic Diffuse Pulmonary Ossification
por: Edahiro, Ryuya, et al.
Publicado: (2018)

Monitoring antibody binding to T cells in a pembrolizumab‐treated patient with lung adenocarcinoma on hemodialysis
por: Osa, Akio, et al.
Publicado: (2019)

Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
por: Osa, Akio, et al.
Publicado: (2018)

Improvement of exertional dyspnea and breathing pattern of inspiration to expiration after bronchial thermoplasty
por: Miki, Keisuke, et al.
Publicado: (2018)

THU374 Fulminant Type 1 Diabetes Mellitus And DKA Secondary To Pembrolizumab
por: Iqbal, Iqra, et al.
Publicado: (2023)

Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)
por: Tachihara, Motoko, et al.
Publicado: (2018)

Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral
por: Kusuki, Kazuhisa, et al.
Publicado: (2020)

Early development of pembrolizumab‐induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma
por: Jang, Soo Yeon, et al.
Publicado: (2022)

IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis
por: Mitarai, Yuki, et al.
Publicado: (2021)

Pembrolizumab-Induced Delayed-Onset Hepatitis
por: Kanaoka, Kensuke, et al.
Publicado: (2020)

Diabetic ketoacidosis after the second dose of SARS-CoV-2 mRNA vaccination in a patient with pembrolizumab-induced fulminant type 1 diabetes
por: Nishino, Kohei, et al.
Publicado: (2022)

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
por: Hosoya, Kazutaka, et al.
Publicado: (2021)

Congenital syphilis presenting as fulminant early-onset sepsis
por: Shah, Mayur Sureshbhai, et al.
Publicado: (2022)

Fulminant type 1 diabetes mellitus induced by pembrolizumab in a patient with urothelial carcinoma: A case report
por: Tohi, Yoichiro, et al.
Publicado: (2019)

Case report: Posterior reversible encephalopathy syndrome, an adverse effect of lenvatinib and pembrolizumab combination therapy, in a patient with advanced endometrial cancer
por: Matsuura, Yuki, et al.
Publicado: (2023)

Clinically diagnosed late-onset fulminant Wilson’s disease without cirrhosis: A case report
por: Amano, Takahiro, et al.
Publicado: (2018)

Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patients
por: Iwahori, Kota, et al.
Publicado: (2022)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
por: Morita, Mitsunori, et al.
Publicado: (2020)

Pembrolizumab‐caused polyradiculoneuropathy as an immune‐related adverse event
por: Kurashige, Takashi, et al.
Publicado: (2021)

Fulminant Tracheobronchial Aspergillosis in an Apparently Healthy Adult
por: Moribuchi, Hayato, et al.
Publicado: (2020)

Single-cell multi-omics analysis identifies two distinct phenotypes of newly-onset microscopic polyangiitis
por: Nishide, Masayuki, et al.
Publicado: (2023)

Rapid Onset of Takotsubo Cardiomyopathy Induced by an Infusion Reaction to Pembrolizumab in a Patient with NSCLC
por: Okamatsu, Yuki, et al.
Publicado: (2020)

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial
por: Matsumoto, Hiromi, et al.
Publicado: (2021)

LBSUN292 Learning Lesson From A Case of Fulminant Type 1 Diabetes Mellitus Shortly After Pembrolizumab Treatment
por: Phan, Van, et al.
Publicado: (2022)

Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event
por: Adhikari, Narayan, et al.
Publicado: (2016)

Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case Reports
por: Thomsen, Kenneth, et al.
Publicado: (2018)

Aseptic Meningitis as an Immune-Related Adverse Event after Pembrolizumab
por: Lima, Gian, et al.
Publicado: (2019)

Adverse Endocrine-Related Effects of Pembrolizumab Precipitating Severe Hyponatremia
por: Baldawi, Muaamar B, et al.
Publicado: (2022)

Fulminant type 1 diabetes mellitus with anti‐programmed cell death‐1 therapy
por: Okamoto, Masahide, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_54nhkfm3ju8clros9iglaba9sk